While potent antifungal agents exist that are microbicidal for Candida, the attributable mortality of candidemia is approximately 38%, even with currently available antifungal therapy. The use of either passive or active immuno-therapy against Candida is a promising alternative to standard anti- fungal therapy of its potential to avoid the problems association with heavy use of antifungal agents. Our long range goal is to identify dominant candidal adhesions and use these adhesions as targets for active or passive immunotherapy for serious candidal infections. During the current project period, we determined that the C. albicans gene, ALS1, likely encodes an adhesin that mediated attachment to endothelial and epithelial cells. This gene is a member of the ALS gene family. To date, approximately 11 members of the ALS gene family have been identified. However, the sequence of only two of these genes have been published. It is our central hypothesis that the ALS gene family encodes the major adhesion of C. albicans. It is likely that the different ALS proteins mediate adherence to different host constituent ligands. We propose to systematically examine selected members of the ALS gene family to determine which of them encode adhesins that mediate the binding of C. albicans to endothelium epithelium, and other host constituents. This information will be used to develop techniques to block the adherence of the organism to host tissues by using either passive or active immunization.
The Specific Aims for this project are to i) obtain thje full-length sequence of ALS6 and ALS94-98; ii) determine if the above ALS genes encode adhesions to endothelial cells, epithelial cells and selected other host constituents, and determine the ligands on the cell surface to which they bind; iii) determine if antibodies against specific ALS proteins block the adherence of C. albicans to endothelial and epithelial cells, and the selected host constituents in vitro; and iv) determine if antibodies against specific ALS proteins protect mice from mucosal and hematogenously disseminated candidal infections. We will identify adhesion as targets for active and passive immunization strategies. These adhesins are highly attractive targets for immunotherapy by themselves, have the potential to be used in combination with the targets identified by other projects in the Mycology Research Unit.

Project Start
2002-04-01
Project End
2003-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
8
Fiscal Year
2002
Total Cost
$196,218
Indirect Cost
City
Torrance
State
CA
Country
United States
Zip Code
90502
Boxx, Gayle M; Kozel, Thomas R; Nishiya, Casey T et al. (2010) Influence of mannan and glucan on complement activation and C3 binding by Candida albicans. Infect Immun 78:1250-9
Boxx, Gayle M; Nishiya, Casey T; Kozel, Thomas R et al. (2009) Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans. Mol Immunol 46:473-80
Zhang, Mason X; Bohlman, M Charlotte; Itatani, Carol et al. (2006) Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect Immun 74:362-9
Lillegard, Joseph B; Sim, Robert B; Thorkildson, Peter et al. (2006) Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 193:1589-97
Toenjes, Kurt A; Munsee, Suzanne M; Ibrahim, Ashraf S et al. (2005) Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 49:963-72
Cutler, J E (2005) Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 5:383-92
Granger, Bruce L; Flenniken, Michelle L; Davis, Dana A et al. (2005) Yeast wall protein 1 of Candida albicans. Microbiology 151:1631-44
Ibrahim, Ashraf S; Spellberg, Brad J; Avenissian, Valentina et al. (2005) Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 73:999-1005
Spellberg, Brad J; Ibrahim, Ashraf S; Avenissian, Valentina et al. (2005) The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 73:6191-3
VandenBerg, Alysia L; Ibrahim, Ashraf S; Edwards Jr, John E et al. (2004) Cdc42p GTPase regulates the budded-to-hyphal-form transition and expression of hypha-specific transcripts in Candida albicans. Eukaryot Cell 3:724-34

Showing the most recent 10 out of 63 publications